Metabolic Research
Semaglutide
GLP-1 receptor agonist approved in the United States for specific diabetes and weight-management indications, depending on product and labeling.
EstablishedApproved medicine
View peptide →
Includes both approved medicines with cardiovascular outcome data and experimental peptides studied in vascular models.
Metabolic Research
GLP-1 receptor agonist approved in the United States for specific diabetes and weight-management indications, depending on product and labeling.
View peptide →
Metabolic Research
Dual GIP and GLP-1 receptor agonist approved in the United States for specific diabetes and weight-related indications, depending on product labeling.
View peptide →